AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34144489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral endometriomas
Number of subjects: 310
Study 34144489 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral adnexal adhesions in bilateral endometriomas
Number of subjects: 310
Study 33213532 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who committed to pay dowry upon marriage
Number of subjects: 250
Study 33213532 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who suspected their husbands of having extramarital affairs
Number of subjects: 250
Study 33213532 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who reported having poor spousal communication
Number of subjects: 250
Study 34753540 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caffeine (10 mg/kg maintenance dose)
Number of subjects: 162
Study 34753540 — intervention group
Group type: COMPARATOR
Intervention: Low-dose caffeine (5 mg/kg maintenance dose)
Number of subjects: 162
Study 34753540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 32588685 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 32588685 — intervention group
Group type: COMPARATOR
Intervention: Placebo sham group
Number of subjects: 0
Study 34411802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernix caseosa
Number of subjects: 64
Study 34411802 — intervention group
Group type: COMPARATOR
Intervention: Mother's milk
Number of subjects: 64
Study 32445503 — intervention group
Group type: COMPARATOR
Intervention: Sintering temperature at 1350°C
Number of subjects: 120
Study 32445503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintering temperature at 1450°C
Number of subjects: 120
Study 32445503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintering temperature at 1600°C
Number of subjects: 120
Study 32445503 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickness of 1 mm
Number of subjects: 120
Study 32445503 — intervention group
Group type: COMPARATOR
Intervention: Thickness of 1.5 mm
Number of subjects: 120
Study 33826415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with IPC plus LLLT
Number of subjects: 42
Study 33826415 — intervention group
Group type: COMPARATOR
Intervention: IPC therapy alone
Number of subjects: 42
Study 33190242 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 81
Study 32229444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner at 21:00
Number of subjects: 8
Study 32229444 — intervention group
Group type: COMPARATOR
Intervention: Dinner at 18:00
Number of subjects: 8
Study 32229444 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dinner (vegetable and rice at 18:00 and vegetable and the main dish at 21:00)
Number of subjects: 8
Study 35334197 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg baricitinib
Number of subjects: 1200
Study 35334197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg baricitinib
Number of subjects: 1200
Study 35334197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 35334197 — intervention group
Group type: COMPARATOR
Intervention: 4 mg baricitinib vs Placebo
Number of subjects: 1200
Study 35334197 — intervention group
Group type: COMPARATOR
Intervention: 2 mg baricitinib vs Placebo
Number of subjects: 1200
Study 35334197 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg)
Number of subjects: 1200
Study 33099092 — intervention group
Group type: EXPERIMENTAL
Intervention: Back foot heel in full contact with the floor
Number of subjects: 52
Study 33099092 — intervention group
Group type: EXPERIMENTAL
Intervention: Back foot heel raised off the floor
Number of subjects: 52
Study 33099092 — intervention group
Group type: EXPERIMENTAL
Intervention: Back foot non weight bearing (NWB)
Number of subjects: 52
Study 32843306 — intervention group
Group type: EXPERIMENTAL
Intervention: ERICA (Embryo Ranking Intelligent Classification Algorithm)
Number of subjects: 1231
Study 35482101 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 0
Study 35482101 — intervention group
Group type: COMPARATOR
Intervention: Balloon-based strategies
Number of subjects: 0
Study 32648397 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife therapy at cervical spine area, acupuncture at specific acupoints, sodium hyaluronate eye drops (1 drop 5-6 times a day) for 3 courses (1 week each).
Number of subjects: 84
Study 32648397 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at specific acupoints, sodium hyaluronate eye drops (1 drop 5-6 times a day) for 3 courses (1 week each).
Number of subjects: 84
Study 32648397 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate eye drops (1 drop 5-6 times a day) for 3 courses (1 week each).
Number of subjects: 84
Study 33534859 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 941
Study 33534859 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy arms
Number of subjects: 941
Study 33197451 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 90
Study 33197451 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 90
Study 33197451 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica gel
Number of subjects: 90
Study 33197451 — intervention group
Group type: COMPARATOR
Intervention: Control (Fresh lenticules)
Number of subjects: 90
Study 36370817 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher recirculation air rates in fully occupied cabins
Number of subjects: 559
Study 36370817 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher recirculation air rates in half-occupied cabins
Number of subjects: 559
Study 36370817 — intervention group
Group type: COMPARATOR
Intervention: Full occupancy
Number of subjects: 559
Study 36370817 — intervention group
Group type: COMPARATOR
Intervention: Half occupancy
Number of subjects: 559
Study 33637882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy)
Number of subjects: 236
Study 33637882 — intervention group
Group type: COMPARATOR
Intervention: Modified Busulfan-Cyclophosphamide (Bu-Cy) only
Number of subjects: 236
Study 33637882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy) in patients with active disease
Number of subjects: 236
Study 33637882 — intervention group
Group type: COMPARATOR
Intervention: Modified Busulfan-Cyclophosphamide (Bu-Cy) only in patients with active disease
Number of subjects: 236
Study 35317785 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of care employing general practitioners (GPs) in RACFs
Number of subjects: 0
Study 34598692 — intervention group
Group type: EXPERIMENTAL
Intervention: HOP‐UP‐PT program (Home‐based Older Persons Upstreaming Prevention‐Physical Therapy) delivered by physical therapists over nine encounters (six in-person, three telerehabilitation) spanning seven months.
Number of subjects: 144
Study 34598692 — intervention group
Group type: EXPERIMENTAL
Intervention: HOP‐UP‐PT program participants (EG)
Number of subjects: 144
Study 34598692 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) continued their usual physical activity routines during the same time frame.
Number of subjects: 144
Study 32583295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.1 mg
Number of subjects: 100
Study 32583295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.35 mg
Number of subjects: 100
Study 32583295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.5 mg
Number of subjects: 100
Study 32583295 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1 mg
Number of subjects: 100
Study 32583295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine (all doses)
Number of subjects: 100
Study 35196591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% nepafenac eye drops, thrice daily for 2 weeks
Number of subjects: 160
Study 35196591 — intervention group
Group type: COMPARATOR
Intervention: 0.09% bromfenac eye drops, twice daily for 2 weeks
Number of subjects: 160
Study 33823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the bilateral tempo-parietal junction at 2.0 mA for 10 days, combined with computer-based cognitive training.
Number of subjects: 0
Study 34020928 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 124
Study 33902584 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1690
Study 33902584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 32112591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5‐fluorouracil (5‐FU) injections
Number of subjects: 43
Study 32112591 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone (TAC) injections
Number of subjects: 43
Study 32112591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 5‐FU and TAC injections
Number of subjects: 43
Study 32371116 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe system (GI‐Genius, Medtronic) during high‐definition colonoscopies
Number of subjects: 685
Study 32371116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CADe system) during high‐definition colonoscopies
Number of subjects: 685
Study 35902633 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) machine learning algorithm
Number of subjects: 12747
Study 33596848 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined ultra-short regimen guided by molecular DST to pyrazinamide via whole-genome sequencing (WGS) for 24-32 weeks (pyrazinamide-susceptible) or 36-44 weeks (pyrazinamide-resistant)
Number of subjects: 354
Study 33596848 — intervention group
Group type: COMPARATOR
Intervention: WHO injectable-containing shorter regimen for 36-44 weeks depending on time of sputum smear conversion
Number of subjects: 354
Study 33596848 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined ultra-short regimen
Number of subjects: 354
Study 32019783 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 88
Study 32019783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 34587650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (NO3, 9 mmol)
Number of subjects: 8
Study 34587650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 35606868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day e-learning educational programme on perinatal psychological issues
Number of subjects: 115
Study 35606868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 115
Study 33048267 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Life Events (NLEs) in the academic domain
Number of subjects: 319
Study 33048267 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed a grade in school
Number of subjects: 319
Study 33048267 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative change in acceptance by peers
Number of subjects: 319
Study 32554878 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols
Number of subjects: 16
Study 32554878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrogallic acid
Number of subjects: 16
Study 32554878 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols concentration
Number of subjects: 16
Study 34398703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 85
Study 34398703 — intervention group
Group type: COMPARATOR
Intervention: Study skills active control
Number of subjects: 85
Study 34398703 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 85
Study 33487513 — intervention group
Group type: EXPERIMENTAL
Intervention: (R/S)-ketamine
Number of subjects: 30
Study 33487513 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine
Number of subjects: 30
Study 33487513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32352353 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% EGCG dentin pretreatment + etch-and-rinse
Number of subjects: 33
Study 32352353 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% EGCG dentin pretreatment + self-etch
Number of subjects: 33
Study 32352353 — intervention group
Group type: COMPARATOR
Intervention: etch-and-rinse
Number of subjects: 33
Study 32352353 — intervention group
Group type: COMPARATOR
Intervention: self-etch
Number of subjects: 33
Study 35228305 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 26
Study 35228305 — intervention group
Group type: COMPARATOR
Intervention: Variable PSV
Number of subjects: 26
Study 35690253 — intervention group
Group type: EXPERIMENTAL
Intervention: BAND
Number of subjects: 30
Study 35690253 — intervention group
Group type: EXPERIMENTAL
Intervention: BRACE
Number of subjects: 30
Study 35690253 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 30
Study 32469388 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH protein diet (1.6 g protein/kg/d)
Number of subjects: 33
Study 32469388 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW protein diet (0.5 g protein/kg/d)
Number of subjects: 33
Study 32469388 — intervention group
Group type: EXPERIMENTAL
Intervention: NO protein diet (0.15 g protein/kg/d)
Number of subjects: 33
Study 32469388 — intervention group
Group type: EXPERIMENTAL
Intervention: D2O ingestion
Number of subjects: 33
Study 32469388 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily MyoPS rates during immobilization
Number of subjects: 33
Study 32732142 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 2320
Study 32732142 — intervention group
Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (IIV3-BV)
Number of subjects: 2320
Study 32732142 — intervention group
Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (IIV3-BY)
Number of subjects: 2320
Study 34118255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation up to size 25.04
Number of subjects: 55
Study 34118255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation up to size 25.06
Number of subjects: 55
Study 34118255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation up to size 30.04
Number of subjects: 55
Study 34118255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation up to size 30.06
Number of subjects: 55
Study 34118255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preparation in the MM canal)
Number of subjects: 55
Study 32947474 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin supplementation (treatment group)
Number of subjects: 48
Study 32947474 — intervention group
Group type: COMPARATOR
Intervention: Control (no antithrombin supplementation)
Number of subjects: 48
Study 34931346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab treatment
Number of subjects: 0
Study 34605666 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognition+TM intervention (an hourlong workshop on effective learning strategies and self-awareness plus a second hourlong workshop on time management and procrastination)
Number of subjects: 17
Study 34605666 — intervention group
Group type: COMPARATOR
Intervention: Baseline Metacognition intervention (an hourlong workshop focused on effective learning strategies and self-awareness)
Number of subjects: 17
Study 32160632 — intervention group
Group type: COMPARATOR
Intervention: Universal iodine supplementation (control group)
Number of subjects: 208
Study 32160632 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted iodine supplementation (study group)
Number of subjects: 208
Study 35832418 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL + ELD
Number of subjects: 98
Study 35832418 — intervention group
Group type: COMPARATOR
Intervention: ZOL
Number of subjects: 98
Study 32187610 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of The Whiplash Book
Number of subjects: 0
Study 32187610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training or information)
Number of subjects: 0
Study 36030839 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 89
Study 34621054 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121 at 3, 10 and 30 mg kg-1
Number of subjects: 48
Study 34621054 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121 at 30 mg kg-1
Number of subjects: 48
Study 32965230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mHealth intervention
Number of subjects: 42
Study 32965230 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 42
Study 33731364 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS lenses (n=65)
Number of subjects: 128
Study 33731364 — intervention group
Group type: COMPARATOR
Intervention: Control-to-DIMS group (n=55)
Number of subjects: 128
Study 33731364 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS lenses vs historical control
Number of subjects: 128
Study 33731364 — intervention group
Group type: COMPARATOR
Intervention: Control-to-DIMS vs historical control
Number of subjects: 128
Study 33337436 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard duration varenicline
Number of subjects: 103
Study 33337436 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended duration varenicline
Number of subjects: 103
Study 33337436 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters
Number of subjects: 103
Study 33337436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 32985421 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket health expenditure (OOPE)
Number of subjects: 235
Study 32985421 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophic health expenditure (CHE)
Number of subjects: 235
Study 32985421 — intervention group
Group type: COMPARATOR
Intervention: Type of village (presence of public health-care facility)
Number of subjects: 235
Study 32985421 — intervention group
Group type: COMPARATOR
Intervention: Presence of health insurance
Number of subjects: 235
Study 32985421 — intervention group
Group type: COMPARATOR
Intervention: Gender of the head of the family
Number of subjects: 235
Study 35267206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy (NRT) and Quitline support
Number of subjects: 748
Study 35267206 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal care)
Number of subjects: 748
Study 35267206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (those who quit before surgery)
Number of subjects: 748
Study 35267206 — intervention group
Group type: COMPARATOR
Intervention: Control group (those who quit before surgery)
Number of subjects: 748
Study 33302926 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured foot orthoses
Number of subjects: 88
Study 33302926 — intervention group
Group type: COMPARATOR
Intervention: Sham flat insoles
Number of subjects: 88
Study 34117385 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival (Tconj) local anaesthetic administration
Number of subjects: 30
Study 34117385 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous (Tskin) local anaesthetic administration
Number of subjects: 30
Study 34580055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiasp plus pramlintide fully closed-loop system
Number of subjects: 28
Study 34580055 — intervention group
Group type: COMPARATOR
Intervention: Fiasp-alone hybrid closed-loop system
Number of subjects: 28
Study 36265196 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐Hz rTMS
Number of subjects: 64
Study 36265196 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 64
Study 34542060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides (SNAGs)
Number of subjects: 40
Study 34542060 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 35536699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior contextual information about the trolley problem
Number of subjects: 119
Study 35536699 — intervention group
Group type: COMPARATOR
Intervention: No prior contextual information about the trolley problem
Number of subjects: 119
Study 34132192 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab
Number of subjects: 463
Study 34132192 — intervention group
Group type: EXPERIMENTAL
Intervention: aflibercept
Number of subjects: 463
Study 34132192 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 463
Study 36031810 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 6635
Study 36031810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6635
Study 34412057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 3938
Study 34412057 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 3938
Study 34088513 — intervention group
Group type: COMPARATOR
Intervention: Oral metronomic therapy with etoposide (50 mg, day 1 to 14) and cyclophosphamide (50 mg, day 1 to 28, every 4 weeks)
Number of subjects: 75
Study 34088513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (400 mg once daily) in addition to etoposide and cyclophosphamide
Number of subjects: 75
Study 34088513 — intervention group
Group type: COMPARATOR
Intervention: Oral metronomic therapy with etoposide and cyclophosphamide
Number of subjects: 75
Study 34088513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib in addition to etoposide and cyclophosphamide
Number of subjects: 75
Study 34088513 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment in Arm B
Number of subjects: 75
Study 34088513 — intervention group
Group type: COMPARATOR
Intervention: Serum VEGF and PDGF levels in both arms
Number of subjects: 75
Study 32766862 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct to consumer referral pathway (e.g., digital and print media, registry emails)
Number of subjects: 313
Study 32766862 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider referral pathway (i.e., electronic health record [EHR] order and provider recommendation)
Number of subjects: 313